Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for ca...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.859152/full |
| _version_ | 1819158852101210112 |
|---|---|
| author | Joanna Kapeleris Joanna Kapeleris Majid Ebrahimi Warkiani Arutha Kulasinghe Arutha Kulasinghe Ian Vela Ian Vela Ian Vela Liz Kenny Rahul Ladwa Rahul Ladwa Kenneth O’Byrne Kenneth O’Byrne Chamindie Punyadeera Chamindie Punyadeera Chamindie Punyadeera |
| author_facet | Joanna Kapeleris Joanna Kapeleris Majid Ebrahimi Warkiani Arutha Kulasinghe Arutha Kulasinghe Ian Vela Ian Vela Ian Vela Liz Kenny Rahul Ladwa Rahul Ladwa Kenneth O’Byrne Kenneth O’Byrne Chamindie Punyadeera Chamindie Punyadeera Chamindie Punyadeera |
| author_sort | Joanna Kapeleris |
| collection | DOAJ |
| description | Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for cancer diagnosis and prognosis in many parts of the world. However, due to tumour heterogeneity and accessibility issues, liquid biopsy is emerging as a game changer for both cancer diagnosis and prognosis. Liquid biopsy is the analysis of tumour-derived biomarkers in body fluids, which has remarkable advantages over the use of traditional tumour biopsy. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are two main derivatives of liquid biopsy. CTC enumeration and molecular analysis enable monitoring of cancer progression, recurrence, and treatment response earlier than traditional biopsy through a minimally invasive liquid biopsy approach. CTC-derived ex-vivo cultures are essential to understanding CTC biology and their role in metastasis, provide a means for personalized drug testing, and guide treatment selection. Just like CTCs, ctDNA provides opportunity for screening, monitoring, treatment evaluation, and disease surveillance. We present an updated review highlighting the prognostic and therapeutic significance of CTCs and ctDNA in NSCLC. |
| first_indexed | 2024-12-22T16:31:14Z |
| format | Article |
| id | doaj.art-0388ec7d13c34349b8d98c62dd24435b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T16:31:14Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-0388ec7d13c34349b8d98c62dd24435b2022-12-21T18:20:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.859152859152Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An UpdateJoanna Kapeleris0Joanna Kapeleris1Majid Ebrahimi Warkiani2Arutha Kulasinghe3Arutha Kulasinghe4Ian Vela5Ian Vela6Ian Vela7Liz Kenny8Rahul Ladwa9Rahul Ladwa10Kenneth O’Byrne11Kenneth O’Byrne12Chamindie Punyadeera13Chamindie Punyadeera14Chamindie Punyadeera15Saliva and Liquid Biopsy Translational Laboratory, The Centre for Biomedical Technologies, The School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD, AustraliaTranslational Research Institute, Brisbane, QLD, AustraliaSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, AustraliaTranslational Research Institute, Brisbane, QLD, AustraliaThe School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaThe School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, AustraliaAustralian Prostate Cancer Research Centre, Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, AustraliaDepartment of Urology, Princess Alexandra Hospital, Woolloongabba, QLD, AustraliaSchool of Medicine, University of Queensland, Royal Brisbane and Women’s Hospital, Central Integrated Regional Cancer Service, Queensland Health, Brisbane, QLD, AustraliaDepartment of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, QLD, AustraliaSchool of Medicine, University of Queensland, Herston, QLD, AustraliaTranslational Research Institute, Brisbane, QLD, AustraliaDepartment of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, QLD, AustraliaSaliva and Liquid Biopsy Translational Laboratory, The Centre for Biomedical Technologies, The School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD, AustraliaTranslational Research Institute, Brisbane, QLD, Australia0Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery and Menzies Health Institute Queensland, Griffith University, Nathan, QLD, AustraliaDespite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for cancer diagnosis and prognosis in many parts of the world. However, due to tumour heterogeneity and accessibility issues, liquid biopsy is emerging as a game changer for both cancer diagnosis and prognosis. Liquid biopsy is the analysis of tumour-derived biomarkers in body fluids, which has remarkable advantages over the use of traditional tumour biopsy. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are two main derivatives of liquid biopsy. CTC enumeration and molecular analysis enable monitoring of cancer progression, recurrence, and treatment response earlier than traditional biopsy through a minimally invasive liquid biopsy approach. CTC-derived ex-vivo cultures are essential to understanding CTC biology and their role in metastasis, provide a means for personalized drug testing, and guide treatment selection. Just like CTCs, ctDNA provides opportunity for screening, monitoring, treatment evaluation, and disease surveillance. We present an updated review highlighting the prognostic and therapeutic significance of CTCs and ctDNA in NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2022.859152/fulllung cancerNSCLCcirculating tumour DNA (ctDNA)circulating tumour cell (CTC)liquid biopsy |
| spellingShingle | Joanna Kapeleris Joanna Kapeleris Majid Ebrahimi Warkiani Arutha Kulasinghe Arutha Kulasinghe Ian Vela Ian Vela Ian Vela Liz Kenny Rahul Ladwa Rahul Ladwa Kenneth O’Byrne Kenneth O’Byrne Chamindie Punyadeera Chamindie Punyadeera Chamindie Punyadeera Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update Frontiers in Oncology lung cancer NSCLC circulating tumour DNA (ctDNA) circulating tumour cell (CTC) liquid biopsy |
| title | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
| title_full | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
| title_fullStr | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
| title_full_unstemmed | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
| title_short | Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update |
| title_sort | clinical applications of circulating tumour cells and circulating tumour dna in non small cell lung cancer an update |
| topic | lung cancer NSCLC circulating tumour DNA (ctDNA) circulating tumour cell (CTC) liquid biopsy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.859152/full |
| work_keys_str_mv | AT joannakapeleris clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT joannakapeleris clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT majidebrahimiwarkiani clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT aruthakulasinghe clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT aruthakulasinghe clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT ianvela clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT ianvela clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT ianvela clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT lizkenny clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT rahulladwa clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT rahulladwa clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT kennethobyrne clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT kennethobyrne clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT chamindiepunyadeera clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT chamindiepunyadeera clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate AT chamindiepunyadeera clinicalapplicationsofcirculatingtumourcellsandcirculatingtumourdnainnonsmallcelllungcanceranupdate |